Cover Image
市場調查報告書

心肌缺血:開發中產品分析

Myocardial Ischemia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229788
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
心肌缺血:開發中產品分析 Myocardial Ischemia - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 64 Pages
簡介

供給心肌的血流和氧不足就會引起心缺血(心肌缺血)。症狀有身體左側的胸部疼痛(心絞痛),頭或下巴疼痛、肩膀及手腕疼痛、皮膚黏黏的、呼吸困難、噁心及嘔吐等。心肌缺血有可能造成冠狀動脈疾病(動脈粥狀硬化性心血管疾病),凝血,冠狀動脈痙攣與嚴重疾病等症狀。根據研究發現會提升致病風險的因素有香煙,糖尿病,高血壓,血中含高膽固醇或中性脂肪值,運動不足,肥胖,家族病史等。

本報告提供心肌缺血的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您夾雜了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。。

簡介

  • 調查範圍

心肌缺血概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

心肌缺血的治療藥開發企業

  • Angionetics Inc
  • Bayer AG
  • Cellmid Ltd
  • CohBar Inc
  • Lixte Biotechnology Holdings Inc
  • NoNO Inc
  • Omniox Inc
  • Pathfinder Cell Therapy Inc
  • Shire Plc
  • Symic Biomedical Inc
  • ViroMed Co Ltd

藥物簡介

心肌缺血:暫停中的計劃

心肌缺血:開發中止的產品

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9050IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Pipeline Review, H1 2017, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.

Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myocardial Ischemia - Overview
    • Myocardial Ischemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Myocardial Ischemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Myocardial Ischemia - Companies Involved in Therapeutics Development
    • Angionetics Inc
    • Bayer AG
    • Cellmid Ltd
    • CohBar Inc
    • Lixte Biotechnology Holdings Inc
    • NoNO Inc
    • Omniox Inc
    • Pathfinder Cell Therapy Inc
    • Shire Plc
    • Symic Biomedical Inc
    • ViroMed Co Ltd
  • Myocardial Ischemia - Drug Profiles
    • AB-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alferminogene tadenovec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AntimiR-199a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-606583 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMK-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EP-80317 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Humanin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMX-4.80 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pathfinder Cells - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMC-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-030 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Myocardial Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Myocardial Ischemia - Dormant Projects
  • Myocardial Ischemia - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Myocardial Ischemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Myocardial Ischemia - Pipeline by Angionetics Inc, H1 2017
  • Myocardial Ischemia - Pipeline by Bayer AG, H1 2017
  • Myocardial Ischemia - Pipeline by Cellmid Ltd, H1 2017
  • Myocardial Ischemia - Pipeline by CohBar Inc, H1 2017
  • Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
  • Myocardial Ischemia - Pipeline by NoNO Inc, H1 2017
  • Myocardial Ischemia - Pipeline by Omniox Inc, H1 2017
  • Myocardial Ischemia - Pipeline by Pathfinder Cell Therapy Inc, H1 2017
  • Myocardial Ischemia - Pipeline by Shire Plc, H1 2017
  • Myocardial Ischemia - Pipeline by Symic Biomedical Inc, H1 2017
  • Myocardial Ischemia - Pipeline by ViroMed Co Ltd, H1 2017
  • Myocardial Ischemia - Dormant Projects, H1 2017
  • Myocardial Ischemia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Myocardial Ischemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top